-
1.发明授权公开(公告)号：US11834436B2
公开(公告)日：2023-12-05
申请号：US17228815
申请日：2021-04-13
发明人： Guoqiang Wang , Ruichao Shen , Brett Granger , Jing He , Xuechao Xing , Yong He , Jiang Long , Jun Ma , Bin Wang , Yat Sun Or
IPC分类号： C07D401/14 , C07D413/14 , C07D405/14 , C07D409/14 , C07D417/14
CPC分类号： C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
摘要： The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof:
which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).-
公开(公告)号：US20230143250A1
公开(公告)日：2023-05-11
申请号：US17891436
申请日：2022-08-19
发明人： Guoqiang Wang , Jun Ma , Brett Granger , Jiang Long , Bin Wang , Sourav Ghorai , Jing He , Yong He , Xuechao Xing , Ruichao Shen , Yat Sun Or
IPC分类号： C07D265/36 , C07D277/36 , C07C311/29 , C07D217/20 , C07D471/04 , C07D209/18 , C07D209/44 , C07D417/12 , C07D417/04 , C07D307/81
CPC分类号： C07D265/36 , C07D277/36 , C07C311/29 , C07D217/20 , C07D471/04 , C07D209/18 , C07D209/44 , C07D417/12 , C07D417/04 , C07D307/81
摘要： The present invention provides compounds of Formula (I),
pharmaceutical compositions comprising these compounds and methods of using these compounds to provides a method of modulating a HSD17B13 protein for treatment of metabolic disease or liver condition, The present invention relates generally to compounds and pharmaceutical compositions useful as 17β-HSD13 inhibitors. Specifically, the present invention relates to compounds useful as inhibitors of 17β-HSD13 and methods for their preparation and use.-
公开(公告)号：US20220356167A1
公开(公告)日：2022-11-10
申请号：US17197399
申请日：2021-03-10
发明人： Guoqiang Wang , Ruichao Shen , Jiang Long , Jun Ma , Xuechao Xing , Yong He , Brett Granger , Jing He , Bin Wang , Yat Sun Or
IPC分类号： C07D401/14 , C07D417/14 , C07D413/14 , C07D403/12 , C07D403/14 , C07D405/14
摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
公开(公告)号：US11345699B2
公开(公告)日：2022-05-31
申请号：US16688429
申请日：2019-11-19
发明人： Brett Granger , Guoqiang Wang , Ruichao Shen , Jing He , Yong He , Xuechao Xing , Jun Ma , Jiang Long , Bin Wang , Yat Sun Or
IPC分类号： C07D471/04 , C07D401/14 , C07D417/14 , C07D405/14 , C07D413/14
摘要： The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
5.发明申请公开(公告)号：US20220119366A1
公开(公告)日：2022-04-21
申请号：US17228815
申请日：2021-04-13
发明人： Guoqiang Wang , Ruichao Shen , Brett Granger , Jing He , Xuechao Xing , Yong He , Jiang Long , Jun Ma , Bin Wang , Yat Sun Or
IPC分类号： C07D401/14 , C07D413/14 , C07D405/14 , C07D409/14 , C07D417/14
摘要： The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
-
公开(公告)号：US10988458B2
公开(公告)日：2021-04-27
申请号：US16866778
申请日：2020-05-05
发明人： Guoqiang Wang , Ruichao Shen , Jiang Long , Jun Ma , Xuechao Xing , Yong He , Brett Granger , Jing He , Bin Wang , Yat Sun Or
IPC分类号： C07D401/14 , C07D405/14 , C07D403/14 , C07D413/14 , C07D417/14 , C07D403/12
摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
公开(公告)号：US10829486B2
公开(公告)日：2020-11-10
申请号：US16272506
申请日：2019-02-11
发明人： Ruichao Shen , Jun Ma , Guoqiang Wang , Xuechao Xing , Yat Sun Or
摘要： The present invention provides compounds of Formula (I): pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
-
公开(公告)号：US20190194216A1
公开(公告)日：2019-06-27
申请号：US16217749
申请日：2018-12-12
发明人： Yat Sun Or , Jun Ma , Guoqiang Wang , Xuechao Xing , Ruichao Shen , Bin Wang
IPC分类号： C07D491/048 , C07D493/04 , C07D487/04 , C07D417/14
CPC分类号： C07D491/048 , C07D417/14 , C07D487/04 , C07D493/04
摘要： The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
-
公开(公告)号：US10246439B2
公开(公告)日：2019-04-02
申请号：US15988783
申请日：2018-05-24
发明人： Brett Granger , Guoqiang Wang , Ruichao Shen , Jun Ma , Xuechao Xing , Jing He , Yong He , Jiang Long , Bin Wang , Yat Sun Or
IPC分类号： C07D401/14 , C07D487/08 , C07D491/08 , C07D513/04 , C07D417/14
摘要： The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
公开(公告)号：US20180362502A1
公开(公告)日：2018-12-20
申请号：US15988783
申请日：2018-05-24
发明人： Brett Granger , Guoqiang Wang , Ruichao Shen , Jun Ma , Xuechao Xing , Jing He , Yong He , Jiang Long , Bin Wang , Yat Sun Or
IPC分类号： C07D401/14 , C07D417/14 , C07D513/04 , C07D491/08 , C07D487/08
CPC分类号： C07D401/14 , C07D417/14 , C07D487/08 , C07D491/08 , C07D513/04
摘要： The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
-
-
-
-
-
-
-
-
搜索结果
61 条记录 (耗时 0.041 秒)
